The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02–011 Overcomes C797S-Mediated Resistance in Lung Cancer
Yun Jung Choi(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jin Kyung Rho(Ulsan College)
Cited by 5
Related Papers
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
|Experimental & Molecular Medicine|2019|382
Exosomal miR-1260b derived from non-small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2
|Cell Death and Disease|2021|62
Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
|Scientific Reports|2021|58
Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma
|Scientific Reports|2019|26